1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Johnson & Johnson said it reached an agreement to comprehensively resolve the remaining ovarian talc litigation, covering about 76,000 claims, with a $5.5 billion commitment by the company. The deal is conditioned on participation by at least 95% of the remaining claims, and the company said it continues to deny that its talc products cause cancer.
Company commitment of $5.5 billion, with the first payment of no more than $3 billion due in 2027 and no additional payments due before 2028
Agreement conditioned on participation of at least 95% of the remaining claims, including lead plaintiff firms in federal MDL and state court cases
Announced July 27, 2026, following a July 22, 2026 MDL court order requiring plaintiffs to show why remaining claims should not be dismissed
An arbitrator dismissed SELLAS's claims against licensee 3D Medicines on July 24, 2026, and allocated about $1.0 million of 3D Medicines' legal fees and costs to be paid by SELLAS. The filing also gives unaudited cash and cash equivalents of $138.3 million as of June 30, 2026, which may differ materially from the figures in the company's final financial statements. The dismissal removes SELLAS's claims over $13.0 million in disputed milestone payments, while 3D Medicines says it will continue developing galinpepimut-S in Greater China.
On July 24, 2026, the sole arbitrator in the HKIAC arbitration dismissed SELLAS's claims against 3D Medicines.
SELLAS must pay approximately $1.0 million of 3D Medicines' legal fees and costs, as allocated by the arbitrator.
Unaudited cash and cash equivalents were $138.3 million as of June 30, 2026, subject to financial closing procedures.
$191.5 million in potential future milestone payments remained under the license as of March 31, 2026, including the $13.0 million in dispute.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.